/ /

Lynda Charters
Study: Combined SMILE, CXL safe for keratoconus
Combined small-incision lenticule extraction (SMILE) and intrastromal collagen crosslinking (CXL) to treat forme fruste keratoconus is safe, efficient, accurate, predictable, and stable for treating keratoconus for at least 1 year, according to Enrique O. Graue Hernandez, MD, MSc.
Tubes or trabeculectomy to prevent glaucoma: That is the question
Shunt implantation and trabeculectomy are important procedures in the battle to prevent blindness from glaucoma, and tubes are steadily gaining in popularity possibly because of the more predictable postoperative course.
Dual-optic lens accommodates vision at all distances
A dual-optic accommodating IOL (Synchrony, Abbott Medical Optics) seems to have met the presbyopic challenge by providing good vision at far and intermediate distances.
Trifocal IOL facilitates intermediate vision
A diffractive trifocal IOL (FineVision, PhysIOL) provides a peak modulation transfer function for intermediate vision.
Finding the culprit in long-standing ptosis and diplopia
In difficult neuro-ophthalmology cases, selecting the correct imaging tools and trusting the skill of the radiologist are highly important.
Strategies for repairing late orbital fractures
Computer-assisted techniques help achieve the best possible results in complicated cases of anatomic reconstruction.
Managing post-occlusion with advanced fluidics
An ophthalmologist compares two currently available fluidics systems and their ability to recover after occlusion is interrupted.
A novel index for diagnosing keratoconus
The Bowman’s ectasia index (BEI) may be a novel index for diagnosing keratoconus with a sensitivity and specificity of 100% for both, according to study results reported by Mohamed F. Abou Shousha, MD, PhD.
Why prompt CXL treatment vital in keratoconus diagnosis
Children and adolescents with keratoconus may have rapid progression between the ages of 8 and 19 years and immediate treatment with corneal crosslinking may stop that progression.
Bevacizumab more cost-effective for ROP than laser
Treating retinopathy of prematurity (ROP) has a great value in societal terms due to the potentially long lifespans ahead of these patients. However, a comparison of bevacizumab (Avastin, Genentech) and laser for treating ROP found that drug therapy was more cost effective than laser, even with extended follow-up periods, according to Michael J. Geske, MD.


View Results